Tokyo Medical and Dental University

Kyoto University

Mie University

Chugai Seiyaku Kabushiki Kaisha

Dai Nippon Printing Co., Ltd.

Intellectual Property Strategy Network, Inc.

United Immunity, Co., Ltd.

Kazunari Akiyoshi

Hiroshi Shiku

Naozumi Harada

Hiroshi Kiyono

Tsuyoshi Shimoboji

Yoshikazu Yuki

Tai Hirakura

Naohiro Seo

Nobuyuki Morimoto

Ikuo Morita

Takashi Nakai

Daisuke Muraoka

Shin-ichi Sawada

Junko Nakamura

Tsuguhiro Kaneda

Tomonori Nochi

Shinichiro Nomura

Shinichi Sawada

Fumiyasu Momose

An object is to provide a technique of forming CpG oligonucleotides and hydrophobized polysaccharides into complexes. This object is achieved by a complex comprising a modified CpG oligonucleotide containing a hydrophobic group A having a sterol skeleton, and a modified polysaccharide containing a hydrophobic group B.

Complex

The disclosure provides a method for preparing exosomes using: (i) a step for ultrafiltering a sample containing at least one exosome; and (ii) a step for subjecting the sample that can be obtained from step (i) to anion exchange column chromatography.

Exosome production method

A long-chain peptide antigen includes a plurality of epitopes. An interepitope sequence located between two of the plurality of epitopes contains four to ten consecutive tyrosines. The long-chain peptide antigen may be administered to a patient together with a hydrophobized polysaccharide, such as cholesterol-modified pullulan, and/or an adjuvant, such as CpG oligo DNA.

Long chain antigen containing interepitope sequence that promotes antigen presentation to T cells

Therapeutic agents effective for treating cell-proliferative diseases contain extracellular vesicles (exosomes) released from cytotoxic T cells or miRNA obtained from extracellular vesicles (exosomes) released from cytotoxic T cells, such as human CD8+ T cells. Such therapeutic agents suppress the proliferation of mesenchymal cells surrounding cancer cells, e.g., by killing the mesenchymal cells, such that the cancer cells become isolated and unable to metastasize. Cell-proliferative diseases are thus treatable by administering such a therapeutic agent to a patient.

Therapeutic agent associated with suppression of proliferation and metastasis of tumor, which comprises exosomes released from cytotoxic T cells and targets cancer stromal/mesenchymal cells

The present invention provides a nasal vaccine for, and a production method therefor. This nasal vaccine formulation for primates includes a complex of PspA, i.e. the vaccine antigen, and a nanogel in which hydrophobic cholesterol is added, as side chains, to pullulan having amino groups. Furthermore, the present invention provides a production method for the nasal vaccine formulation for primates.

[object Object]

It is intended to efficiently inject into a target cell, a substance charged within a liposome. The present inventors have found that connexin synthesized within a liposome is introduced as connexon having a gap junction function into the liposome membrane. Specifically, the liposome according to the present invention is a liposome in which connexon composed of connexin synthesized by an in-vitro protein synthesis system is incorporated in a state of having a gap junction function.

Liposome and method for injecting substance to cell using this liposome

The present invention provides a composition comprising a hyaluronic acid derivative having a crosslinking group(s) and a hydrophilic polysaccharide derivative having a hydrophobic group(s), wherein the hyaluronic acid derivative having a crosslinking group(s) is prepared by crosslinkage formation reaction in hyaluronic acid or a derivative thereof having a crosslinkable group(s) in the presence of the hydrophilic polysaccharide derivative wherein the hydrophilic polysaccharide derivative may have a crosslinkable group(s).

Hybrid gel comprising chemically crosslinked hyaluronic acid derivative and  pharmaceutical composition comprising the same

A mucosal vaccine for the prevention or treatment of microbial infections is described that is capable of inducing vaccine antigen-specific immune responses in an organism without the addition of a mucosal adjuvant. The mucosal vaccine comprises a composite of a nanogel comprising a hydrophilic polysaccharide having a cationic functional group and a hydrophobic cholesterol added thereto as a side chain and a vaccine antigen. The vaccine is administered via a mucosal route.

Mucosal vaccine using cationic nanogel

The present invention provides a hydrophobic group-introduced hyaluronic acid derivative comprising at least one repeating unit represented by the formula (I): wherein R, R, R, R, Z, n, Ra, Y, and Xare as defined in the specification.

Growing community of inventors

Kyoto, Japan

Kazunari Akiyoshi